This insights guide explains how Joint Scientific Consultations (JSCs), introduced under the EU Health Technology Assessment Regulation (HTAR effective January 12, 2025), enable health technology developers to obtain early, coordinated advice on evidence requirements. JSCs are designed to reduce duplication across EU member states and support faster patient access to innovative medicines and medical devices. The guide outlines how early dialogue with HTA bodies helps align clinical development, evidence generation, and data packages needed for future Joint Clinical Assessments and national HTA submissions. It highlights best practices for preparing for JSCs, including clear research questions, robust development plans, and cross-functional alignment. Overall, the guide positions JSCs as a

Join for free to read